Downloads: 37

Files in This Item:
File Description SizeFormat 
j.chembiol.2021.08.003.pdf1.32 MBAdobe PDFView/Open
Title: Targeted elimination of mutated mitochondrial DNA by a multi-functional conjugate capable of sequence-specific adenine alkylation
Authors: Hidaka, Takuya
Hashiya, Kaori
Bando, Toshikazu
N., Ganesh Pandian
Sugiyama, Hiroshi
Author's alias: 日髙, 拓也
橋谷, かおり
坂東, 俊和
ナマシヴァヤム, ガネシュ・パンディアン
杉山, 弘
Keywords: pyrrole-imidazole polyamide
mitochondrial DNA
DNA alkylation
DNA mutation
mitochondrial disease
designer small molecule
Issue Date: Apr-2022
Publisher: Elsevier BV
Journal title: Cell Chemical Biology
Volume: 29
Issue: 4
Start page: 690
End page: 695
Thesis number: e5
Abstract: Mutations in mitochondrial DNA (mtDNA) cause mitochondrial diseases, characterized by abnormal mitochondrial function. Although eliminating mutated mtDNA has potential to cure mitochondrial diseases, no chemical-based drugs in clinical trials are capable of selective modulation of mtDNA mutations. Here, we construct a class of compounds encompassing pyrrole-imidazole polyamides (PIPs), mitochondria-penetrating peptide, and chlorambucil, an adenine-specific DNA-alkylating reagent. The sequence-selective DNA binding of PIPs allows chlorambucil to alkylate mutant adenine more efficiently than other sites in mtDNA. In vitro DNA alkylation assay shows that our compound 8950A-Chb(Cl/OH) targeting a nonpathogenic point mutation in HeLa S3 cells (m.8950G>A) can specifically alkylate the mutant adenine. Furthermore, the compound reduces the mtDNA possessing the target mutation in cultured HeLa S3 cells. The programmability of PIPs to target different sequences could allow this class of compounds to be developed as designer drugs targeting pathogenic mutations associated with mitochondrial diseases in future studies.
Description: ミトコンドリアの変異DNAを減らす化合物の開発. 京都大学プレスリリース. 2021-08-27.
Deleting DNA to treat mitochondrial diseases. 京都大学プレスリリース. 2021-08-27.
Rights: © 2021. This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license.
The full-text file will be made open to the public on 21 April 2023 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.
This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
DOI(Published Version): 10.1016/j.chembiol.2021.08.003
PubMed ID: 34450110
Related Link:
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

This item is licensed under a Creative Commons License Creative Commons